NEW YORK, Dec. 14, 2018 (GLOBE NEWSWIRE) -- Levi & Korsinsky announces it has commenced an investigation of bluebird bio, Inc. (“bluebird” or “the Company”) (NASDAQGS: BLUE) concerning possible violations of federal securities laws.

On December 1, 2018, bluebird issued a press release informing investors that it had “announced new long-term data from the completed Phase 1/2 Northstar (HGB-204) study of investigational LentiGlobin™ gene therapy in patients with transfusion-dependent β-thalassemia (TDT) and from the ongoing Phase 1/2 HGB-206 study of LentiGlobin in patients with sickle cell disease (SCD) today at the 60th Annual Meeting of the American Society of Hematology (ASH).” Then on December 3, 2018, Seeking Alpha published an article asserting that “results were lower than initial data reported a year ago indicating a lower rate of production of anti-sickling hemoglobin.” On this news, shares of bluebird stock fell $6.39 per share, or 5.2%, to close at $116.50 on December 3, 2018. To obtain additional information, go to:

https://www.zlk.com/pslra-1/bluebird-bio-inc-loss-form

or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972.

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:   
Levi & Korsinsky, LLP
Eduard Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
Tel: (212) 363-7500
Toll Free:  (877) 363-5972
Fax: (212) 363-7171
www.zlk.com